Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356777 | 0.85 | AURKA (0.33) | DGAT1AXL | |
| SCHEMBL1354651 | 0.85 | PDE1B (0.34) | DGAT1 | |
| SCHEMBL1357173 | 0.84 | CDK8 (0.31) | — | |
| SCHEMBL2320459 | 0.75 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL29538822 | 0.72 | PIM1 (0.40) | DGAT1 | |
| SCHEMBL21484370 | 0.72 | PIM1 (0.40) | DGAT1 | |
| SCHEMBL2753800 | 0.71 | DGAT1 (0.41) | DGAT1AXL | |
| SCHEMBL1354642 | 0.71 | PDE1B (0.31) | — | |
| SCHEMBL29285150 | 0.71 | DGAT1 (0.38) | DGAT1AXL | |
| SCHEMBL30690645 | 0.70 | IRAK4 (0.35) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569316-B1 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2569316-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011143459-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110281842-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281842-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | DGAT1 4674/4885AXL 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.